Denver, CO—New research assessing trends and outcomes following PCI among nonagenarians supports the use of the therapy in patients regardless of their age. The results, presented at a moderated ...

DANVERS, Mass.--(BUSINESS WIRE)-- Today, Abiomed (NASDAQ: ABMD) launches a cutting-edge digital education platform called CAMP PCI, which stands for Coronary Artery & Myocardial Protected Percutaneous ...

WASHINGTON — In the first randomized clinical trial to compare optimal medical therapy alone with PCI in patients with a coronary chronic total occlusion, the therapeutic strategy was noninferior to ...

The first study evaluating Medicare patients undergoing percutaneous coronary intervention (PCI) in ambulatory surgery centers (ASCs) demonstrated good safety outcomes, such as mortality and adverse ...

The dawn of 2020 saw the world battling the worst pandemic of our times. The crisis made us realize the limitations of current knowledge with respect to the constant uncertainties of the future, thus, ...

"This analysis along with other recent data suggest P2Y12 inhibitor monotherapy is the preferred antiplatelet approach for secondary prevention and is better than aspirin."—Michael C. McDaniel, MD, ...

A Denmark-based observational study has found that, even in a country with a universal, tax-financed health care system, patients with lower socioeconomic status undergoing primary percutaneous ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces new PROTECT III study data that demonstrates reduced rates of MACCE (composite of death, stroke, myocardial infarction and repeat ...

In patients with acute MI, utilization of percutaneous coronary intervention (PCI) is lower in states that publicly report outcomes data, according to a new study published in JAMA. Despite the ...

The median reported annual cost for Massachusetts catheterization laboratories to meet their public reporting requirements was between $100,000 and $200,000 yearly, ranging from $0 to $50,000 to more ...